GSK Plc is reportedly in talks to buy cancer treatment maker Nuvalent Inc. for $9 billion to $10 billion, according to the Financial Times. The potential transaction would be a major strategic acquisition in oncology and could be accretive to GSK’s late-stage pipeline, though no deal has been confirmed. The report is likely to move both stocks and has sector-level relevance for large-cap biotech M&A.
GSK Plc is reportedly in talks to buy cancer treatment maker Nuvalent Inc. for $9 billion to $10 billion, according to the Financial Times. The potential transaction would be a major strategic acquisition in oncology and could be accretive to GSK’s late-stage pipeline, though no deal has been confirmed. The report is likely to move both stocks and has sector-level relevance for large-cap biotech M&A.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
